普通外文研报
Replay: Corporate Access: Conversations with the C-Suite 2026 – EU Healthcare – Roche (ROG.S)
研报英文原文证据摘录
Replay: Corporate Access: Conversations with the C-Suite 2026 – EU Healthcare – Roche (ROG.S)
Equity Research
27 May 2026
Replay: Corporate Access
Conversations with the C-Suite
2026 – EU Healthcare – Roche
(ROG.S) European Pharmaceuticals,
Biotechnology & Life Sciences
Roche CEO expressed confidence in 1) breast cancer (gire James Gordon
approval in Oct, >$11bn peak), 2) multiple sclerosis +44 (0)20 7116 2784
james.gordon@barclays.com
(comfortable on fene safety, >$4bn peak), 3) obesity Barclays, UK
(GLP1/GIP P2 at ADA, filing by '28), 4) broader pipeline (19 Yihan Li, PhD
NME readouts by '30), 5) margins, and 6) ROP's AI +44 (0)20 3555 3563 yihan.li@barclays.com
differentiation. Barclays, UK
Shirley Chen, PhD
+44 (0)20 7773 2109
Please see below replay information for the event held on shirley.chen@barclays.com
Thursday, 21 May 2026 at 1:30pm – 2:30pm UTC Barclays, UK
Sidhartha Modi
This replay is strictly and solely for the benefit of the intended recipients. Barclays Events Terms of +91 (0)22 6175 1326
Service and the Barclays Events Privacy Notice sidhartha.modi@barclays.com
Barclays, UK
Watch Charles Pitman-King, CFA +44 (0)20 3134 6023
charles.pitman-king@barclays.com
This transcript/recording is provided in an unedited format. Barclays is not responsible for the Barclays, UK
recording quality or any transcription errors or omissions.
Appearances by Third-Party Speakers: Any views or opinions expressed by third-party speakers
during this event are solely those of the speaker and do not represent the views or opinions of
Barclays. Barclays is not responsible for, and makes no warranties whatsoever as to, the
information or opinions contained in any written, electronic, audio or video presentations by any
third-party speakers at the event (“Third-Party Content”).
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器